Historically, it has been labor intensive for RPCI researchers to obtain accurate clinical data from multiple disparate sources in a HIPAA compliant manner. To improve efficiency, RPCI established the Clinical Data Network (CDN) Shared Resource, an operational network of people, databases and IT tools working together to consistently collect, abstract, retrieve, integrate, process, link to bio-specimens, and deliver clinical data in a cost-effective manner. It is the meaningful integration of people, research infrastructures and processes, and Information Technology (IT) resources that makes CDN a unique, nimble and effective shared resource. In fact, thanks to the CDN, researchers at RPCI today can get reliable clinical data in three to six days rather than the three to six weeks required before: In the two years of its existence, the CDN has been successfully developed into a shared resource, and seamlessly integrated into the RPCI translational research process. It is already being successfully used by an increasing number of CCSG peer reviewed members with high user satisfaction. The CDN is led by Carmelo Gaudioso, MD, MBA, PhD, Director of Biomedical Informatics. The CDN provides specialized data management technologies, services, and expertise to CCSG members conducting non-interventional research. It guides investigators through the protocol development process, including regulatory and data requirements, and facilitates the review and approval by Disease Site Research Groups (DSRGs) for their use of bio-specimens and data. It provides Honest Broker (HB) service for the delivery of de-identified data and the re-identification for the subsequent delivery of foliow-up data in a HIPAA compliant manner. To establish interoperability across the disparate databases and facilitate data integration and sharing, the CDN facilitates the creation and adoption of standard data dictionaries and data standards. The CDN collaborates with other Shared Resources, notably the Pathology Resource Network (PRN) and the Data Bank and BioRepository (DBBR), for the annotation and the selection of bio-specimens based on clinical-pathological characteristics. To improve the value of the services provided to CCSG members. Dr. Gaudioso and his staff work closely with the scientific programs to better understand their research and related data requirements. First priority for use is given to peer-review-funded RPCI CCSG members;second priority to non-peer-review- funded CCSG members;third priority to non-members and academic collaborators;and last priority to external users. During the reporting period, the Clinical Data Network Shared Resource has served 28 members from 6 research programs, with 37% utilization by CCSG members with peer reviewed funding. The CCSG support provides 6% of the overall proposed budget.

Public Health Relevance

The CDN provides cost-effective abstraction, retrieval, integration, processing and delivery of accurate and reliable HIPAA-compliant clinical data, with linkages to bio-specimens. This is critical for translational research, and overcomes historical obstacles to cross-platform information integration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738388
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$71,552
Indirect Cost
$28,302
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki et al. (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27:679-93
Goossens, Maria E; Isa, Fatima; Brinkman, Maree et al. (2016) International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health 74:30
Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589
Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67
Sexton, Sandra; Tulowitzki, Ryan; Jones, Craig A et al. (2016) Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. Clin Exp Nephrol 20:162-8
Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
Austin, David C; Strand, Douglas W; Love, Harold L et al. (2016) NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate 76:1004-18
Rohrbach, Daniel J; Rigual, Nestor; Arshad, Hassan et al. (2016) Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma. J Biomed Opt 21:18002
Chinnam, Meenalakshmi; Wang, Xiaoling; Zhang, Xiaojing et al. (2016) Evaluating Effects of Hypomorphic Thoc1 Alleles on Embryonic Development in Rb1 Null Mice. Mol Cell Biol 36:1621-7

Showing the most recent 10 out of 1099 publications